Effects of Delayed Cord Clamping on 4-Month Ferritin Levels, Brain Myelin Content, and Neurodevelopment: A Randomized Controlled Trial.
Effects of Delayed Cord Clamping on 4-Month Ferritin Levels, Brain Myelin Content, and Neurodevelopment: A Randomized Controlled Trial.
复制标题
DOI:
10.1016/j.jpeds.2018.06.006
复制
发表时间:
2018-12
期刊:
影响因子:
--
通讯作者:
Padbury JF
中科院分区:
文献类型:
--
作者:
Mercer JS;Erickson-Owens DA;Deoni SCL;Dean DC 3rd;Collins J;Parker AB;Wang M;Joelson S;Mercer EN;Padbury JF
To evaluate whether placental transfusion influences brain myelination at 4 months of age. A partially blinded, randomized controlled trial was conducted at a level III maternity hospital in the US. Seventy-three healthy term pregnant women and their singleton fetuses were randomized to either delayed umbilical cord clamping (DCC, >5 minutes) or immediate clamping (ICC, <20 seconds). At 4 months of age, blood was drawn for ferritin levels. Neurodevelopmental testing (Mullen Scales of Early Learning) was administered, and brain myelin content was measured with magnetic resonance imaging. Correlations between myelin content and ferritin levels and group-wise DCC vs ICC brain myelin content were completed. In the DCC and ICC groups, clamping time was 172 ± 188 seconds vs 28 ± 76 seconds (P < .002), respectively; the 48-hour hematocrit was 57.6% vs 53.1% (P < .01). At 4 months, infants with DCC had significantly greater ferritin levels (96.4 vs 65.3 ng/dL, P = .03). There was a positive relationship between ferritin and myelin content. Infants randomized to the DCC group had greater myelin content in the internal capsule and other early maturing brain regions associated with motor, visual, and sensory processing/function. No differences were seen between groups in the Mullen testing. At 4 months, infants born at term receiving DCC had greater ferritin levels and increased brain myelin in areas important for early life functional development. Endowment of iron-rich red blood cells obtained through DCC may offer a longitudinal advantage for early white matter development. ClinicalTrials.gov: NCT01620008.
登录
查看更多内容
影响因子:
5.7
作者:
Dean DC 3rd;O'Muircheartaigh J;Dirks H;Waskiewicz N;Lehman K;Walker L;Han M;Deoni SC
通讯作者:
Deoni SC
影响因子:
2.3
作者:
Dean, Douglas C., III;Dirks, Holly;O'Muircheartaigh, Jonathan;Walker, Lindsay;Jerskey, Beth A.;Lehman, Katie;Han, Michelle;Waskiewicz, Nicole;Deoni, Sean C. L.
通讯作者:
Deoni, Sean C. L.
影响因子:
26.1
作者:
Andersson, Ola;Lindquist, Barbro;Hellstrom-Westas, Lena
通讯作者:
Hellstrom-Westas, Lena
影响因子:
26.1
作者:
Andersson, Ola;Domellof, Magnus;Hellstrom-Westas, Lena
通讯作者:
Hellstrom-Westas, Lena
影响因子:
3.3
作者:
Deoni, Sean C. L.;Rutt, Brian K.;Jones, Derek K.
通讯作者:
Jones, Derek K.